Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ...

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ...

The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

FDA gives nod of approval to first derived mesenchymal stromal cell therapy for the treatment of pediatric patients with ...

Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.

Hispanic/Latinx communities are the fastest-growing population in the US. In 2023,the US Census Bureau reported that the ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...